Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
French drugmaker Sanofi (SNYNF: Quote,SNY: Quote) Tuesday said the U.S. Food and Drug Administration accepted for review the company's New Drug Application or NDA for Toujeo or insulin glargine [rDNA origin] injection, 300 U/mL, an investigational basal insulin.
The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency for EU countries on May 27.
http://www.rttnews.com/2346315/sanofi-fda-accepts-for-review-nda-for-basal-insulin-toujeo.aspx
The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency for EU countries on May 27.
http://www.rttnews.com/2346315/sanofi-fda-accepts-for-review-nda-for-basal-insulin-toujeo.aspx